This summary was created by AI, based on 1 opinions in the last 12 months.
Overall, experts believe that higher rates are beneficial for insurance companies such as Metlife, with a yield of about 2.9% and favorable growth prospects. The industry as a whole is experiencing a tailwind, as evidenced by the performance of the KIE ETF.
Does not own shares. Financial services and insurance. Valuation is low and could be good time for investors. Does not own shares. Fundamentally a 6/10. Could be volatile. Better options out there for investors.
Metlife is a American stock, trading under the symbol MET-N on the New York Stock Exchange (MET). It is usually referred to as NYSE:MET or MET-N
In the last year, 2 stock analysts published opinions about MET-N. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Metlife.
Metlife was recommended as a Top Pick by on . Read the latest stock experts ratings for Metlife.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
2 stock analysts on Stockchase covered Metlife In the last year. It is a trending stock that is worth watching.
On 2024-12-10, Metlife (MET-N) stock closed at a price of $81.74.
Higher rates are actually good for insurance companies. Yield is about 2.9%, growing at single digits and he prefers double-digit growth. The whole industry has a tailwind, and you can see it if you look at the KIE ETF.